PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of alectinib and pembrolizumab for the adjuvant treatment of non-small cell lung cancer in Japan.
IF 2.4
3区 医学
Q3 ONCOLOGY
引用次数: 0
PMDA关于批准和修订抗癌药物使用注意事项的监管更新；日本批准阿来替尼和pembrolizumab用于非小细胞肺癌的辅助治疗。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
求助全文
约1分钟内获得全文
求助全文
来源期刊
CiteScore
6.80
自引率
3.00%
发文量
175
审稿时长
2 months
期刊介绍：
The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
